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Abstract 
Background: To assess the appropriateness of 
transfusions of fresh frozen plasma (FFP). 
Methods:  In this cross sectional study use of  FFP , by 
different departments,  was analyzed. Management details 
and appropriateness, for the use of FFP, was recorded.  
British Committee for Standards in Haematology (BCSH) 
guidelines were used as standards.  
Results: Four hundred and ninety eight units of FFP 
were used during the study period for 118 transfusion 
episodes. Only 44% episodes of FFP transfusions were 
deemed appropriate. The most common inappropriate uses 
included bleeding with no coagulation test abnormality 
following cardiopulmonary bypass, hypovolaemia and 
hypoproteinaemia.  The proportion of inappropriate 
request was similar between surgical and non surgical 
units.  
 Conclusion:  FFP is frequently used inappropriately. 
Key Words: Fresh frozen plasma. 
 
Introduction 
 
     Fresh frozen plasma (FFP) is a component 
separated from whole blood, stored at below –180C, 
and is good source of all coagulation factors It is life 
saving in multiple coagulation deficiencies but over 
the time it is being administered indiscriminately 
without scientific basis or clinical evidence, particulary 
in underdeveloped countries like Pakistan. Contrary to 
the general belief among clinicians, FFP transfusions 
are not risk free. Allergic reactions1, infectious 
complications, hemolysis, fluid over load, transfusion 
related acute lung injury (TRALI)3 and immune 
suppression can be caused by FFP administration.1,2 
Efforts have been made, mostly in developed countries 
to lay down the guidelines, rationalize its usage and 
educate the medical community employing different 
strategies and tools.3-5  
 
Patients and Methods 
     Patients who received FFP from AFIT between 1st 
September and 31st Nov 2012 were enrolled in this 
study. Referreal units ,indications and other salient 
features were recorded . A transfusion episode in this 
study was defined as one when any number of FFP 
was transfused after each individual request. The 
guidelines published by British Committee for 
Standards in Haematology (BCSH) were used as 
standards(Table I).3 Usage outside these indications 
was deemed inappropriate.  
 
Table-I: Criteria for the use of fresh frozen 
plasma   (BCSH,1992) 
Definite indications for the use of FFP: 
 1-Replacement of single coagulation factor 
deficiency where    specific   factor concentrate is not 
available 
 2-Immediate reversal of warfarin effect 
 3-Acute DIC 
 4-Thrombotic thrombocytopenic purpura 
 
Conditional uses of FFP: in the presence of 
bleeding and disturbed coagulation: 
 1-Massive transfusion 
 2-Liver disease 
 3-Cardiopulmonary bypass surgery 
 
No justification for the use of FFP: 
 1-Hypovolemia 
 2-Plasma exchange 
 3-Nutritional support 
 4-Treatment of immunodeficiency states 
 
Results 
    During the study period, 498 units of FFP were used 
for 118 transfusion episodes in 84 patients. Based on 
these guidelines, appropriate use of FFP was found in 
52 transfusion episodes (44%) and inappropriate in 66 
(56%) of 118 transfusion episodes evaluated. FFP was 
used by both medical and surgical specialties with 
general medicine, intensive care units and cardiac 
surgery being the main users(Table 2).    
    Chronic liver disease followed by DIC was the most 
appropriate indications for FFP infusion(Table 3) . 
Bleeding related to surgery such as cardiovascular and 
thoracic surgery with normal coagulation profile were 
the most common inappropriate indication for FFP 
use. The proportion of inappropriate request was 
similar (58 vs 56) between surgical and non surgical 
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specialties but higher in ICU patients than non ICU (64 
vs 38)   
 
Table2 :Episodes of FFP utilization by  
various departments 
Departments Number 
of 
episodes 
Episodes 
with 
appropriate 
use (%age) 
Episodes with 
inappropriate 
use (%age) 
General 
Medicine 
36 19 (53) 17 (47) 
ICU / CCU 28 10 (36) 18 (64) 
Cardiothoracic 
Surgery 
24 8 (33) 16 (67) 
Oncology/ 
Transplant 
Med. 
10 7 (70) 3 (30) 
General 
Surgery 
8 3 (38) 5 (62) 
Paediatrics 7 3 (43) 4 (57) 
Obs. and 
Gynae. 
5 2 (40) 3 (60) 
Total 118 52 (44) 66 (56) 
ICU = Intensive Care Unit, CCU = Coronary Care Unit 
 
Table 3:Evaluation of FFP usage according to 
the clinical indications 
 No. of 
transfusion  
episodes 
No. of 
FFP 
infused 
Appropriate uses 
Liver disease 16 62 
DIC 14 48 
Post op bleeding with 
deranged coagulation profile 
10 42 
Massive transfusion 08 36 
Reversal of warfarin effects 02 08 
Factor deficiency 02 06 
Inappropriate uses 
Surgery related with normal 
coagulation profile 
21 98 
Bleeding caused  with 
normal coagulation profile 
16 80 
Hypoproteinemia 15 64 
Hypovolemia 08 30 
Reversal of heparin 06 24 
                   Total 118 498 
 
Discussion 
      Concerns regarding transfusion-transmitted 
infections and non-availability of blood components in 
developing nations, makes it crucial to optimize FFP 
transfusions and reduce wastage. In Pakistan the 
situation is more urgent due to the fact that there is no 
volunteer donor base, robust viral screening strategies 
are lacking, blood banks are unregulated and  hospital 
audit mechanisms are almost non existent. Data on 
residual risk of viral transmission by blood products is 
lacking  and there is perpetual scarcity of components 
for transfusion as there are very few blood centers 
having facilities for component preparation. Sufficient 
guidelines and recommendations for the transfusion of 
FFP are available in medical literature, although 
mostly from other countries, but FFP usage remains 
often misused. 
      In present study, FFP was used appropriately in 
42% of cases as per published BCSH guidelines. 3 A 
substantial proportion of transfusions were 
inappropriate which is consistent with other studies in 
other parts of the world. In different studies the 
percentage of appropriate use ranges from 27 to 74%. 
(Table 4). 6-10 The spectrum of misuse of FFP reported 
by different countries varies. Indian studies revealed 
that FFP were most frequently being used as 
nutritional supplement for burns, sepsis, 
hypoproteinaemia and as plasma expander and in 
bleeding without coagulopathy. 11 Previous study in 
Pakistan showed inappropriate use in 45% cases that 
was mostly used intraoperatively.12 Similar results 
were published from Malaysia.13 Cardiothoracic 
surgeries revealed a substantial inappropriate usage of 
FFP .14,15 The cause of bleeding during cardiovascular 
surgery is more frequently attributed to platelets and 
requires more rational therapy. 18 This clinical 
situation has also been studied in detail by Gleb et al 
who observed that the multiple coagulation factors do 
fall  during cardiovascular surgery but this is transient 
and never critical (i.e. < 30% of normal). 16  Thus, 
routine perioperative use of FFP is unnecessary and 
exposes patients to unnecessary risks, including 
additional source of antithrombin III, that can produce 
heparin rebound.17 The rational approach, advocated 
by BCHC guidelines is to advise FFP only if there is 
proven coagulation abnormality.  
There is no justification for the administration 
of FFP as volume expander or as nutritional 
supplement. Safer alternatives, such as crystalloid, 
synthetic colloids or human albumin solutions are 
available for this purpose. High cost of  human 
albumin discourages its use in hypoprotienemia in 
developing countries. Efforts are therefore, needed to 
establish infrastructure for large scale production of 
albumin in the country.  
     The main indications where FFP have been mostly 
transfused appropriately were the patients with 
chronic liver disease, DIC and prolonged bleeding 
with abnormal coagulation test results. Inappropriate
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Table 4:Audit of FFP usage: various studies 
Country Appropriate use % Guidelines used Reference 
Australian 37 NHMRC/ASBT Schofield et al Med J Aust 2003;178 – 21 
Singapore 27 CAP Chng WJ et al Singapore Med J 2003;44: 574–8 
Indian 33 BCSH Chaudhary R et al ANZ J Surg 
Malaysian 40 CAP Parthiba et al Malays J Pathol 2001;2:41–6 
Indian 40 BCSH Kakkar N et al Transfus Med 2004;14:231–35 
UK 66 BCSH Jones HP et al Transfus Med 1998;8:37-41 
Pakistani 55 BCSH Hameedullah et al J Pak Med Assoc 2000;50:253–6 
UK 47 CMA Luk C et al CMAJ 2002;166:1539-40 
Venezuelan 51 BCSH Marti-Carvajal et al Int J Qual Health Care 1999;11:391–5 
Australian 74 NHMRC/ASBT Hui C-H et al Internal Med J 2005;35:283-8 
UK 62 NIH con confs Thomas A et al J Clin Path 1991; 44 : 734 –7 
UK 66 BCSH Eagleton et al Transfus Med 2000; 10:1- 6 
NHMRC/ASBT = National Health and Medical Research Council / Australasian Society for Blood Transfusion Guidelines, CAP = College of 
American Pathologists;CMA = Canadian Medical Association, NIH con confs = National Institute of Health consensus conferences  
 
use of blood components leads to the risk of 
transfusion-transmitted infections and wastage of  
precious human resource in developing countries.18,19   
Modification of FFP request forms with inclusion of 
laboratory evidence of coagulation defects, education 
of the staff at entry level and periodic audit of 
transfusion practices examined by the Hospital 
Transfusion Committee have been instrumental in 
curtailing the misuse of FFP. 20,21            
 
Conclusion 
Evidence based guidelines are required for the rational 
utilization of FFP.  
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